Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2025)

Crinetics Pharmaceuticals has reported Income from Continuing Operations over the past 9 years, most recently at 122635000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 122635000.0 for Q4 2025, down 52.16% from a year ago — trailing twelve months through Dec 2025 was 464954000.0 (down 56.2% YoY), and the annual figure for FY2025 was 465317000.0, down 56.18%.
  • Income from Continuing Operations for Q4 2025 was 122635000.0 at Crinetics Pharmaceuticals, up from 130091000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CRNX hit a ceiling of 22888000.0 in Q1 2021 and a floor of 130091000.0 in Q3 2025.
  • Median Income from Continuing Operations over the past 5 years was 53412000.0 (2023), compared with a mean of 62145500.0.
  • Biggest five-year swings in Income from Continuing Operations: decreased 20.23% in 2023 and later plummeted 69.33% in 2025.
  • Crinetics Pharmaceuticals' Income from Continuing Operations stood at 30808000.0 in 2021, then crashed by 48.18% to 45652000.0 in 2022, then decreased by 22.53% to 55936000.0 in 2023, then crashed by 44.08% to 80595000.0 in 2024, then crashed by 52.16% to 122635000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 122635000.0 (Q4 2025), 130091000.0 (Q3 2025), and 115657000.0 (Q2 2025) per Business Quant data.